OPKO director granted options on 80,000 shares

OPKO HEALTH director Uppaluri Subbarao V received a grant of stock options covering 80,000 shares of common stock as part of standard director compensation.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

OPKO HEALTH director Uppaluri Subbarao V received a grant of stock options covering 80,000 shares of common stock as part of standard director compensation. The options have an exercise price of $1.42 per share, become exercisable on June 18, 2027, and expire on June 17, 2036.

According to the footnote, on June 18, 2026 the company canceled a prior grant of 50,000 options, granted 30,000 new options, and reissued 50,000 options, resulting in 80,000 options held directly after this award.

Insider Trade Summary

Grant/Award: 80,000 shares

Grant/Award 1 txn

Insider UPPALURI SUBBARAO V

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	80,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 80,000 contracts (Direct)

Footnotes (1)

F1. On June 18, 2026, the Issuer canceled the grant of 50,000 options previously made to the Reporting Person and, as a part of the Issuer's standard director compensation, granted the Reporting Person an option to purchase 30,000 shares, and reissued an option to purchase 50,000 shares of the Issuer's common stock.

Key Figures

Option grant size: 80,000 options Exercise price: $1.42 per share Options exercisable date: June 18, 2027 +4 more

7 metrics

Option grant size 80,000 options Stock Option (Right to Buy) granted to director

Exercise price $1.42 per share Exercise price of granted stock options

Options exercisable date June 18, 2027 Date options become exercisable

Expiration date June 17, 2036 Expiration of stock options

Prior options canceled 50,000 options Canceled grant on June 18, 2026 per footnote

New grant portion 30,000 options New option grant as part of compensation

Reissued options 50,000 options Reissued options to director on June 18, 2026

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, standard director compensation, exercise price

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

standard director compensation financial

"as a part of the Issuer's standard director compensation, granted the Reporting Person an option"

exercise price financial

"conversion_or_exercise_price: "1.4200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OPKO HEALTH (OPK) report for Uppaluri Subbarao V?

OPKO HEALTH reported that director Uppaluri Subbarao V received a grant of stock options for 80,000 shares of common stock. This award is classified as a grant or other acquisition, not an open-market purchase or sale, and is part of standard director compensation.

What are the key terms of the new OPKO HEALTH (OPK) stock options?

The reported stock options cover 80,000 shares of OPKO HEALTH common stock with an exercise price of $1.42 per share. They become exercisable on June 18, 2027 and expire on June 17, 2036, giving the director a long-dated incentive linked to future share performance.

Did Uppaluri Subbarao V buy or sell OPKO HEALTH (OPK) shares in the market?

No open-market buying or selling is shown. The Form 4 reflects a grant of derivative securities—stock options—classified as a grant, award, or other acquisition, with no reported market purchases or sales of OPKO HEALTH common shares by the director in this filing.

How did OPKO HEALTH (OPK) change the director’s prior option grant?

On June 18, 2026, OPKO HEALTH canceled a prior grant of 50,000 options to the director. At the same time, it granted 30,000 new options and reissued 50,000 options, resulting in 80,000 options outstanding for the director after these compensation-related adjustments.

How many OPKO HEALTH (OPK) options does the director hold after this transaction?

Following the award, the director directly holds options on 80,000 shares of OPKO HEALTH common stock. This total is reported as the number of derivative securities beneficially owned after the transaction and reflects the combined effect of the cancellation, new grant, and reissued options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/22/2026 - 05:33 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

UPPALURI SUBBARAO V

(Last)

(First)

(Middle)

OPKO HEALTH, INC.

4400 BISCAYNE BLVD.

(Street)

MIAMI

FLORIDA

33137

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OPKO HEALTH, INC. [ OPK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.42	06/18/2026		A⁽¹⁾		80,000		06/18/2027	06/17/2036	Common Stock	80,000	$0	80,000	D

Explanation of Responses:

1. On June 18, 2026, the Issuer canceled the grant of 50,000 options previously made to the Reporting Person and, as a part of the Issuer's standard director compensation, granted the Reporting Person an option to purchase 30,000 shares, and reissued an option to purchase 50,000 shares of the Issuer's common stock.

	Steven D. Rubin, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR